SCHEMBL963427

SCHEMBL963427

O=C(O)Cc1ccc(OCC(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 1/20 0.49
▸ FFAR1 O14842 1/20 0.49
▸ CA2 P00918 1/20 0.47
▸ CAMK2A Q9UQM7 1/20 0.47
▸ PLA2G4B P0C869 1/20 0.47
▸ SRD5A2 P31213 2/20 0.46
▸ PPARD Q03181 1/20 0.46
▸ AKR1B1 P15121 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ TBXAS1 P24557 1/20 0.44
▸ PTGS1 P23219 2/20 0.44
▸ ABCC4 O15439 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ AKR1C3 P42330 1/20 0.44
▸ AKR1C2 P52895 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9742465 0.84 LMNA (0.56) CA2CAMK2APLA2G4BSRD5A2PPARD
SCHEMBL3644918 0.82 MAPT (0.51) ACACBPLA2G4BLMNATSHRKDM4E
SCHEMBL8478320 0.81 ALOX15 (0.47) FFAR1CA2CAMK2APLA2G4BSRD5A2
SCHEMBL11209134 0.79 CA2 (0.52) FFAR1CA2CAMK2APLA2G4BSRD5A2
SCHEMBL11683055 0.79 PLA2G4B (0.61) FFAR1CA2CAMK2APLA2G4BSRD5A2
SCHEMBL8081319 0.78 FFAR1 (0.61) FFAR1PLA2G4BLMNATSHRKDM4E
SCHEMBL4366529 0.78 PKM (0.56) PLA2G4BSRD5A2TSHRPOLBRXRA
SCHEMBL963654 0.78 ATM (0.54) CA2CAMK2ASRD5A2AKR1B1ALOX15
SCHEMBL11684213 0.77 PLA2G4B (0.69) FFAR1CA2CAMK2APLA2G4BAKR1B1
SCHEMBL9832704 0.77 ALOX15 (0.63) FFAR1CA2CAMK2APLA2G4BSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379553-B1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2013-06-26 — — EP disclosed
US-8349880-B2 Bicyclic compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 — — US disclosed
EP-2379553-A1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION Bristol-Myers Squibb Company (US) 2011-10-26 — — EP disclosed
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-20 — — US disclosed
WO-2010083141-A1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production APP, BACE1, APBA1 ACACB 42/4885FFAR1 2920/4885CA2 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback